Treatment of Infections Caused by ESBL-Producing Bacteria
First-Line Treatment Options
- The World Health Organization recommends carbapenems as the drugs of choice for serious infections caused by Extended-Spectrum Beta-Lactamase (ESBL)-producing bacteria, particularly in critically ill patients, while carbapenem-sparing alternatives should be considered for less severe infections to reduce selection pressure for carbapenem resistance 1, 2
- Group 2 carbapenems (imipenem/cilastatin, meropenem, doripenem) are preferred for critically ill patients with high bacterial loads or elevated β-lactam MICs 1
- Piperacillin/tazobactam may be considered for stable patients with mild to moderate infections 1
- Ceftolozane/tazobactam + metronidazole is effective against ESBL-producing Enterobacteriaceae and can preserve carbapenems 2, 3
- Ceftazidime/avibactam + metronidazole has demonstrated activity against ESBL-producers and some KPC-producing organisms 2, 4
Treatment Algorithm Based on Infection Severity
- For critical illness/septic shock, the first choice is Group 2 carbapenems (meropenem, imipenem) 1
- For moderate infections, alternatives include Piperacillin/tazobactam (extended infusion) 1 and Ceftolozane/tazobactam + metronidazole 2, 3
- For mild infections, fluoroquinolones may be considered if susceptibility is confirmed and the patient has a beta-lactam allergy 1, 5
Special Considerations
- Treatment selection should consider local epidemiology of resistance 1, 5
- In areas with high carbapenem-resistant Klebsiella pneumoniae, carbapenem-sparing regimens are strongly recommended 2, 6
- Fluoroquinolones should be avoided in regions with fluoroquinolone resistance rates >20% among E. coli isolates 5
Common Pitfalls to Avoid
- Overuse of carbapenems leads to selection pressure and emergence of carbapenem-resistant organisms 2
- Ignoring local resistance patterns can lead to treatment failure 1, 5
- Delayed source control can lead to inadequate treatment of intra-abdominal infections 1